News

The stock is known to soar on good news.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.

Healthcare stocks are attracting attention in a market broadening beyond AI-driven tech names, and now make up a big chunk of the IBD 50 list.

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.

GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.

Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]

Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated last spring, and Foundayo just opened a scalable oral channel to more than ... Eli Lilly Price Prediction: The Case for Double-Digit Upside

If you sort all the top politicians with a portfolio of above $1 million using their annual gains, who do you expect at the top? Likely Nancy Pelosi, but that’s not the case. A Republican Senator named Ashley Moody has gained 310% in the past year using her portfolio. Her portfolio and her (lack of) ... New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks

Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.

U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.

Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

The abbreviated week in the market could set the tone for the back half of 2026.

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.